2025-12-19 - Analysis Report
Here's a comprehensive report on Hims & Hers Health (HIMS), combining the provided data points and analysis:

**Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.

**1. Return Rate Comparison with S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 124.48%
*   **VOO Cumulative Return:** 73.05%
*   **Divergence:**
    *   **Current:** 68.3
    *   **Relative Divergence:** 37.9

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) in terms of cumulative return. However, the relative divergence of 37.9 indicates that the current outperformance is in the lower end of its historical fluctuation range against VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta    | Cap(B) |
|------------|---------|--------|---------|---------|--------|
| 2019-2021  | -42.0%  | 74.4%  | -81.0%  | 0.0     | 1.5    |
| 2020-2022  | -19.0%  | 78.6%  | -18.0%  | -0.0    | 1.5    |
| 2021-2023  | -65.0%  | 78.6%  | -67.0%  | -0.1    | 2.0    |
| 2022-2024  | 119.0% | 79.4%  | 98.0%  | -0.0    | 5.5    |
| 2023-2025  | 129.0% | 80.8%  | 65.0%  | 0.1     | 7.9    |

**Analysis:**

*   **CAGR:**  The CAGR shows a significant turnaround from negative returns in earlier periods to substantial positive returns in the more recent 2022-2024 and 2023-2025 periods. This indicates a growth phase for the company.
*   **MDD:**  The Maximum Drawdown (MDD) is consistently high, suggesting significant volatility in the stock's price.
*   **Alpha:** The Alpha values reflect periods of underperformance compared to a benchmark (negative Alpha) followed by strong outperformance in recent years (positive Alpha).
*   **Beta:** The Beta values are close to zero or slightly negative. This suggests the stock's price movements are not strongly correlated with the overall market.
*   **Cap(B):** The Market Cap has increased significantly over time, reflecting the company's growth.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 34.77
*   **Previous Close:** 34.97
*   **Change:** -0.57
*   **5-day SMA:** 36.012
*   **20-day SMA:** 37.258
*   **60-day SMA:** 44.8839

**Analysis:**  The stock price has recently decreased. The 5-day and 20-day SMAs are below the 60-day SMA, indicating a potential short-term downward trend.

**3. Technical Indicators and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 32.66 (Approaching oversold territory)
*   **PPO:** 0.0261
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00)
*   **Recent (20 days) relative divergence change:** 1.1 (+): Short-term increase
*   **Expected Return:** 24.2% (over 2 years, compared to S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates the stock is nearing oversold territory, which *could* suggest a potential buying opportunity (but this is just one indicator).
*   The positive change in relative divergence indicates some recent short-term upward movement.
*   The high expected return suggests analysts are optimistic about the long-term prospects of HIMS relative to the S&P 500.
*   The Hybrid Signal suggests a strong buy recommendation with monthly investments.
*   The slight price decrease indicates the fluctuation issue.

**4. Recent News & Significant Events:**

*   **Volatility and Expansion:** News highlights recent volatility and expansion efforts.
*   **Insider Selling:** Michael Chi sold shares, which *could* be interpreted negatively (but could also be for personal reasons).
*   **Share Repurchase Program:** A $250 Million share repurchase program authorization.  This is generally seen as a positive signal, as it indicates the company believes its stock is undervalued.
*   **Technology-Driven Care & Profitability:**  Hims & Hers is scaling technology-driven care as profitability evolves.
*   **Partnerships and Price Surge:** Assessing Hims & Hers Health After Latest Partnerships and a 50% Year-to-Date Price Surge.
*   **Why Is Hims & Hers Stock Falling?**  The Motley Fool explores a recent stock price decline and considers whether it presents a buying opportunity.

**Analysis:** The news is mixed.  The share repurchase program and focus on scaling technology-driven care are positive signals.  However, the insider selling and articles questioning a recent price fall warrant caution.  The articles noting "volatility" and exploring "should investors buy the dip?" highlight the inherent risk in the stock.

**4-2. Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.93 (Hold)
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00
*   **Number of Opinions:** 12
*   **Recent Rating Changes:** No recent rating changes provided.

**Analysis:** The analyst consensus is a "Hold" rating, suggesting a neutral outlook on the stock. The average target price of $44.67 indicates a potential upside from the current price, but the wide range between the high and low target prices ($85 to $25) reflects uncertainty among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-11-03 | 0.07  | 0.60 B$ |
| 2025-08-04 | 0.19  | 0.54 B$ |
| 2025-05-05 | 0.22  | 0.59 B$ |
| 2024-11-04 | 0.35  | 0.40 B$ |
| 2025-11-03 | 0.35  | 0.40 B$ |

**Analysis:**

*   The revenue has generally been increasing over the past year.
*   The EPS has fluctuated.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30  | $0.60B  | 73.80%        |
| 2025-06-30  | $0.54B  | 76.39%        |
| 2025-03-31  | $0.59B  | 73.50%        |
| 2024-12-31  | $0.48B  | 76.81%        |
| 2024-09-30  | $0.40B  | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE     |
|--------------|---------|---------|
| 2025-09-30  | $0.58B  | 2.72%   |
| 2025-06-30  | $0.56B  | 7.55%   |
| 2025-03-31  | $0.55B  | 9.01%   |
| 2024-12-31  | $0.48B  | 5.46%   |
| 2024-09-30  | $0.44B  | 17.18%  |

**Analysis:**

*   **Revenue:** Revenue has shown consistent growth over the past five quarters.
*   **Profit Margin:**  Profit margins are strong and have been relatively stable, indicating good cost control.
*   **Equity:**  Equity has been steadily increasing, demonstrating a strengthening financial position.
*   **ROE:** ROE has fluctuated but indicates the company is generating returns on its equity. The recent decrease in ROE may be a concern.

**7. Comprehensive Analysis (Summary):**

Hims & Hers Health (HIMS) presents a mixed picture.

**Positives:**

*   **Strong Revenue Growth:** The company has demonstrated consistent revenue growth.
*   **High Profit Margins:**  Healthy profit margins indicate efficient operations.
*   **High Expected Return:** The expected return of 24.2% is attractive.
*   **Share Repurchase Program:** Signifies confidence in the company's future.
*   **Positive Alpha:** The company has significantly outperformed a benchmark in recent years.

**Negatives & Risks:**

*   **High Volatility:** The stock exhibits high volatility, as evidenced by the MDD values.
*   **Insider Selling:** Recent insider selling can be a negative indicator.
*   **Analyst Consensus: Hold:** Indicates a neutral outlook.
*   **Fluctuating EPS** Indicates instability of Earnings per share
*   **Decreasing ROE:** The decreasing return on equity in recent quarters is worrisome.
*   **Stock Price Decline:** The recent stock price decline and articles questioning "buying the dip" highlight potential concerns.

**Overall Conclusion:**

HIMS appears to be a growth company with significant potential, but also carries considerable risk. The recent stock price decline, mixed news sentiment, and analyst consensus "Hold" rating suggest caution. Potential investors should carefully consider their risk tolerance and conduct further due diligence before investing. The strong revenue growth and positive long-term outlook are encouraging, but the volatility and mixed signals from the market require careful consideration.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.